Delcath Systems (NASDAQ:DCTH – Get Free Report) released its earnings results on Monday. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.26, FiscalAI reports. The business had revenue of $35.10 million for the quarter, compared to analyst estimates of $25.99 million. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%.
Delcath Systems Stock Performance
Delcath Systems stock opened at $14.93 on Monday. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $17.42. The firm has a 50 day moving average price of $15.45 and a two-hundred day moving average price of $12.44. The firm has a market cap of $518.06 million, a price-to-earnings ratio of 1,494.49 and a beta of 0.62.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the stock. BTIG Research lifted their price objective on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Zacks Research cut Delcath Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a report on Friday, August 7th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and an average price target of $26.67.
Read Our Latest Report on Delcath Systems
Delcath Systems Company Profile
Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.
Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.
Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.
Read More
- Five stocks we like better than Delcath Systems
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
